About us

Senior Management

Péterfi Zalán

Zalán Péterfi

MD, PhD

ZALÁN IS THE CSO OF VASCULAR GROUP

With MD and PhD degrees from Semmelweis University, postdoctoral training at Harvard Medical School; Zalán is a Life-science focused manager, Harvard-trained scientist, ex-Mckinsey consultant with extensive experience in the pharma, biotech and health industry.

He is passionate about and experienced in topics where both scientific/medical expertise and management/business excellence are essential to drive maximum impact

Péter Puskás

MD, MBA

PÉTER IS THE CEO OF THE VASCULAR GROUP

Peter has a degree in Medicine (MD), a Masters Degree in Economics from Corvinus University, and also obtained his MBA degree at INSEAD, Singapore. He has been with McKinsey and Company for 10+ years where amongst others he supported multiple top tier pharma company across various topics including R&D, strategy, operations, business development and M&A.

He was the CEE regional leader of McKinsey’s healthcare and pharmaceutical practice before joining the Vascular Group in 2021.

NGS service management

Bihari Zoltán

Zoltán Bihari

PhD

ZOLTAN IS THE HEAD OF THE VASCULAR GENETIX NGS LABORATORY

Zoltán is a molecular biologist who earned his PhD in biotechnology from the University of Szeged. During his research career, he was the Head of Department for Metagenomics and then the Head of the GMP-certified Laboratory of Medicine at Bay Zoltán Nonprofit Ltd. for Applied Research. Formerly, Zoltán was the Field Application Specialist of Illumina NGS products at GeneTiCA Ltd.

His main areas of expertise are Next Generation Sequencing, metagenomics and human diagnostics. He has been coordinating R&D&I projects and supervising high-throughput NGS laboratories for 10 years. He is the Founder & CEO of an NGS service provider company, Xenovea Ltd.

Márton Megyeri

PhD, MBA

MÁRTON IS THE HEAD OF BUSINESS DEVELOPMENT

Marton is a bioengineer and holds a PhD in structural biochemistry and protein science. He was a postdoctoral researcher at the Weizmann Institute of Science in Israel. Alongside academic studies he earned an MBA degree.

With 9+ years of bio-pharmaceutical experience and 15+ years of academic track record he is able to integrate regulatory with process development, analytical development in order to deliver successful CMC for pharmaceutical and cell and gene therapy projects. He has participated in several BPD Tpye2 meetings with FDA and Scientific Advice with EMA and his team authored CMC sections of successful IND submissions. He scientifically supported business negotiations and participated on several in-licensing projects.

NGS application experts